Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 16/20 | 0.55 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27007893 | 0.79 | HSD11B1 (0.47) | HSD11B1HPGD | |
| SCHEMBL18182117 | 0.76 | RAB9A (0.43) | HSD11B1TLR8GAAMAPTTP53 | |
| SCHEMBL3043421 | 0.75 | TDP1 (0.52) | GAAMAPTTP53ALDH1A1ALOX15 | |
| SCHEMBL31547677 | 0.75 | TDP1 (0.52) | GAAMAPTTP53ALDH1A1ALOX15 | |
| SCHEMBL13589299 | 0.75 | MAPT (0.35) | HSD11B1TLR8GAAMAPTTP53 | |
| SCHEMBL13589307 | 0.75 | ALDH1A1 (0.47) | GAAMAPTTP53ALDH1A1HPGD | |
| SCHEMBL27007830 | 0.72 | HSD11B1 (0.50) | HSD11B1ALDH1A1HPGD | |
| SCHEMBL9690163 | 0.71 | ALDH1A1 (0.33) | HSD11B1GAAMAPTTP53ALDH1A1 | |
| SCHEMBL9844299 | 0.71 | NR1I2 (0.39) | HSD11B1GAAMAPTTP53ALDH1A1 | |
| SCHEMBL9691041 | 0.71 | RAB9A (0.36) | HSD11B1GAAMAPTTP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1732904-B1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK SHARP & DOHME (US) | 2014-03-19 | — | — | EP | claimed |
| US-8178546-B2 | Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | claimed |
| US-20100256387-A1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK SHARP & DOHME (US) | 2010-10-07 | — | — | US | claimed |
| US-20080255216-A1 | Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | MERCK SHARP & DOHME CORP. | 2008-10-16 | — | — | US | claimed |
| EP-1732904-A4 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO INC (US) | 2007-11-14 | — | — | EP | claimed |
| EP-1732904-A1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | Merck & Co., Inc. (US) | 2006-12-20 | — | — | EP | claimed |
| WO-2005097759-A1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO., INC. (US) | 2005-10-20 | — | — | WO | claimed |
| EP-1732904-B1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK SHARP & DOHME (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8178546-B2 | Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100256387-A1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK SHARP & DOHME (US) | 2010-10-07 | — | — | US | disclosed |
| US-20080255216-A1 | Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | MERCK SHARP & DOHME CORP. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256387-A1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | HSD11B1, HSD11B2, HSD3B1 | HSD11B1 1/4885TLR8 4630/4885GAA 2822/4885 |
| US-20080255216-A1 | Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885TLR8 4534/4885GAA 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.